Core Viewpoint - The company Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced that its innovative drug, Angladiwei Tablets (brand name: Anruiwei), has been included in the National Medical Insurance Directory for 2025, which is expected to enhance market promotion and sales potential for the product [1][2]. Group 1: Product Information - Angladiwei Tablets are the world's first targeted drug for the PB2 subunit of the influenza A virus RNA polymerase, approved for treating adult patients with uncomplicated influenza [2]. - The drug is characterized by rapid action, strong efficacy, and low resistance, providing a cost-effective and accessible treatment option for patients [2]. Group 2: Market Impact - The inclusion of Angladiwei Tablets in the National Medical Insurance Directory is anticipated to positively impact the company's long-term operational development and market presence [2]. - Other core products of the company, including Lai Ru Te Wei Tablets and various other formulations, continue to be listed in the National Medical Insurance Directory, supporting the company's overall product portfolio [1].

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has successfully included its innovative drug, Anladiwei Tablets (brand name: Anruiwei), in the National Medical Insurance Directory for 2025, which is expected to enhance patient access to effective treatment for influenza [1] Group 1: Product Inclusion - Anladiwei Tablets is the first global drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, approved for the treatment of uncomplicated influenza in adults [1] - The drug is characterized by rapid action, strong efficacy, and low resistance, providing a significant option for patients suffering from influenza [1] - Other core products of the company, including Lai Ru Te Wei Tablets and various formulations, continue to be included in the National Medical Insurance Directory [1] Group 2: Market Impact - The inclusion of Anladiwei Tablets in the Class B category of the National Medical Insurance Directory is expected to benefit a larger patient population, offering economical, safe, and accessible medication options [1] - The drug was approved by the National Medical Products Administration in May 2025, marking a significant milestone for the company's respiratory pipeline [1]

Core Viewpoint - Zhongsheng Pharmaceutical's innovative drug, Angladiwei Tablets (brand name: Anruiwei), has been included in the National Medical Insurance Directory for the first time through national medical insurance negotiations [1] Group 1: Company Developments - The company announced that its core product, Lai Ru Te Wei Tablets, along with several other products, continues to be included in the National Medical Insurance Directory [1]

Core Viewpoint - Zhongsheng Pharmaceutical's innovative drug Angladewe Tablets (brand name: Anruiwei) has been included in the National Medical Insurance Directory for the first time through national medical insurance negotiations for 2025 [1] Group 1: Company Developments - The company announced that its core products, including Lai Ru Te Wei Tablets, Compound Thrombus Tong Capsules, Cerebral Thrombus Tong Capsules, Sucralfate Oral Suspension, Carboxymethyl Starch Oral Solution, and Nitazoxanide Eye Drops, have also been included in the National Medical Insurance Directory [1]

Core Viewpoint - Yipinhong (300723) has received approval from the National Medical Products Administration for its oral solution of L-carnitine, indicating a significant step in expanding its product portfolio in the pharmaceutical market [1] Group 1: Product Approvals - Yipinhong's subsidiary has obtained a drug registration certificate for L-carnitine oral solution, which is indicated for primary systemic carnitine deficiency and related symptoms [1] - The approved L-carnitine oral solution is classified as a Category B product under the national medical insurance, with an estimated sales scale of approximately 1.257 billion yuan in 2024 [1] - In addition to L-carnitine, Yipinhong has received approvals for several other drugs, including escitalopram oxalate drops (estimated sales of 1.88 billion yuan in 2024) and clindamycin palmitate ester granules (estimated sales of 100 million yuan in 2024) [2][2] - The company has also received approval for oseltamivir phosphate capsules, which are used for the treatment and prevention of influenza in adults and children [2] Group 2: Innovative Drug Development - Yipinhong has disclosed that its innovative drug APH03621, a GnRH receptor antagonist for endometriosis treatment, has received clinical trial registration acceptance [3] - The company is advancing its gout drug AR882, with global Phase III clinical trials expected to complete enrollment by August 2025, and data from these trials anticipated in 2026 [3]

Core Viewpoint - The company reported a significant decline in performance for 2024, with a revenue of 2.467 billion yuan, down 5.48% year-on-year, and a net loss of 299 million yuan, marking a drastic shift from a profit of 263 million yuan in the previous year [1][4][10] Revenue and Profitability - The company's revenue has been on a downward trend since 2022, with figures of 2.676 billion yuan in 2022, 2.611 billion yuan in 2023, and 2.467 billion yuan in 2024 [2] - The traditional Chinese medicine segment generated 1.318 billion yuan, accounting for 53.93% of total revenue, while chemical drugs contributed 899 million yuan, or 36.81% [2] - The average price of the core product, Compound XueShuanTong series, dropped by 52% after entering national procurement, leading to a revenue decrease of approximately 120 million yuan despite an 18% increase in sales volume [3] Business Segments - The company is undergoing a transformation from traditional Chinese medicine to an innovative pharmaceutical company, focusing on three main business areas: traditional Chinese medicine, chemical drugs, and innovative drugs [1][10] - The chemical generic drug sector is being refined, with six products approved in 2024, while the raw materials and intermediates segment saw a revenue drop of 26.98% to 30.49 million yuan [3][5] R&D and Innovation - The company has a strong commitment to R&D, with a research expense ratio of 10.68% in 2024, despite a decrease from 12.5% in 2023 [8] - The company has halted several clinical projects, resulting in a one-time impairment loss of 207 million yuan, reflecting a focus on core pipelines [8][9] - The innovative drug RAY1225 is projected to generate significant sales in the diabetes and obesity management market, with estimated contributions of 1.369 billion yuan for diabetes and 700 million yuan for weight management by 2033 [9] Asset Management and Impairment - The company recorded an asset impairment loss of 547 million yuan in 2024, primarily due to goodwill impairment related to subsidiaries and R&D projects [6][7] - The goodwill value at the end of 2024 was 318 million yuan, significantly reduced from 530 million yuan in 2023, indicating challenges in integrating acquired assets [6][7] Market Position and Future Outlook - The company is positioned in a critical transition phase, aiming to redefine its industry status and enhance its innovative capabilities [1][10] - The next 2-3 years are crucial for the company to validate its innovative drug commercialization capabilities, with potential risks if core projects face obstacles [10]